Latvian bio tech Printy Med received €50K from Commercialization Reactor Seed Fund

Riga-based bio tech Printy Med, which produces a product for 3D bioprinting and medical devices, received €50K from Latvian Commercialization Reactor Seed Fund. 

Founded in 2023 by Jekaterina Romanova, Kristaps Jaudzems, and Sandra Treide, Printy Med produces chemically modified artificial spider silk for different medical applications. The startup uses the method of bioconjugation, which imitates the native process of spider silk formation. As a result, the team produces artificial fibers which reproduce the properties of natural spider silk. The team can change the material properties and introduce new functionalities enabled by the chemical modification of designed spider silk proteins. The material is fully recycled and 100% biodegradable. It can be used for producing cosmetics, coatings for medical devices, drug delivery systems, tissue regeneration, and bioprinting.

As a scaffolding material, artificial spider silk can be used for the creation of 3D-printed living tissue. Spider silk can substitute the extracellular matrix (ECM) in tissue engineering. ECM provides structural support for cells to attach to and grow in three dimensions. ECM also makes tissues stronger and more elastic and guarantees the possibility of tissue remodeling, for example, for wound healing.

The startup expects to use the product for skin repair, bladder reconstruction, bone regeneration, cartilage regeneration, heart muscle regeneration, and peripheral nerve regeneration.

Founded in 2009 by Nikolai Adamovitch, Commercialization Reactor Seed Fund offers a deep tech-oriented acceleration program in Riga. It invests up to €50K at the pre-seed stage and offers up to €250K as a follow-up investment.